Author: Alâ€Ani, Aysha H.; Prentice, Ralley E.; Rentsch, Clarissa A.; Johnson, Doug; Ardalan, Zaid; Heerasing, Neel; Garg, Mayur; Campbell, Sian; Sasadeusz, Joe; Macrae, Finlay A.; Ng, Siew C.; Rubin, David T.; Christensen, Britt
Title: Review article: prevention, diagnosis and management of COVIDâ€19 in the IBD patient Cord-id: 77903fld Document date: 2020_5_26
ID: 77903fld
Snippet: BACKGROUND: The current COVIDâ€19 pandemic, caused by SARSâ€CoVâ€2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immuneâ€based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complicatio
Document: BACKGROUND: The current COVIDâ€19 pandemic, caused by SARSâ€CoVâ€2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immuneâ€based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those from COVIDâ€19. AIM: To summarise the scale of the COVIDâ€19 pandemic, review unique concerns regarding IBD management and infection risk during the pandemic and assess COVIDâ€19 management options and drug interactions in the IBD population. METHODS: A literature review on IBD, SARSâ€CoVâ€2 and COVIDâ€19 was undertaken and relevant literature was summarised and critically examined. RESULTS: IBD patients do not appear to be more susceptible to SARSâ€CoVâ€2 infection and there is no evidence of an association between IBD therapies and increased risk of COVIDâ€19. IBD medication adherence should be encouraged to prevent disease flare but where possible highâ€dose systemic corticosteroids should be avoided. Patients should exercise social distancing, optimise coâ€morbidities and be up to date with influenza and pneumococcal vaccines. If a patient develops COVIDâ€19, immune suppressing medications should be withheld until infection resolution and if trial medications for COVIDâ€19 are being considered, potential drug interactions should be checked. CONCLUSION: IBD patient management presents a challenge in the current COVIDâ€19 pandemic. The primary focus should remain on keeping bowel inflammation controlled and encouraging medication adherence.
Search related documents:
Co phrase search for related documents- abdominal pain and activity report: 1
- abdominal pain and acute ards respiratory distress syndrome: 1, 2, 3, 4
- abdominal pain and acute respiratory illness: 1, 2, 3, 4, 5, 6, 7, 8
- abdominal pain and local protocol: 1, 2
- abdominal pain and low infection: 1, 2, 3
- abdominal pain and lung injury: 1, 2, 3, 4, 5
- acid testing and acute respiratory illness: 1, 2, 3
- acid testing and low infection: 1, 2, 3, 4, 5
- acid testing and lung injury: 1, 2, 3
- activity report and lung injury: 1, 2
- acute ards respiratory distress syndrome and local protocol: 1, 2, 3
- acute ards respiratory distress syndrome and long incubation: 1
- acute ards respiratory distress syndrome and low infection: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and lung field: 1, 2, 3
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- acute ards respiratory distress syndrome and lung injury perpetuate: 1
- acute pneumonia pneumonitis and lung injury: 1, 2
Co phrase search for related documents, hyperlinks ordered by date